BridgeBio Oncology Therapeutics, Inc. 8-KCurrent Reports (8-K / ad hoc)

Financial Statements

Item 8.01 Other Matters On September 8, 2026, BridgeBio Oncology Therapeutics, Inc. (the “Company”) issued a press release titled “ BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers .” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Also on September 8, 2026, the Company revised its Corporate Presentation in connection with recent corporate updates, a copy of which is being filed as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.